XDH and metabolic dysfunction-associated steatotic liver disease: However, it remains challenging to achieve and sustain such modifications for most patients, and a substantial proportion of them are dramatically lean.[14,15] Many studies have demonstrated XD's efficacy as a hypolipidemic and NAFLD protectant in animal experiments and clinical trials, making it a candidate for future therapy against NAFLD.